Phenotypic heterogeneity in severe hemophilia

H M van den Berg1, P H G De Groot, K Fischer

  • 1Department of Internal Medicine, The Van Creveldkliniek, and Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands. h.m.vandeberg@umcutrecht.nl

Large heterogeneity in bleeding pattern and arthropathy is observed among patients with severe hemophilia. Studies have reported a large variability in bleeding pattern among patients with severe hemophilia. Of special interest are some 10% of the patients with severe hemophilia who only rarely bleed and don't need prophylactic therapy. Prothrombotic risk factors seem to influence phenotype but they can account for only a small part of the heterogeneity. Half-lives for factor VIII (FVIII) range between 7 and 20 h; a significantly shorter half-life has been reported in patients with blood group O and a low von Willebrand antigen level. In addition, thrombin generation tests have been used to differentiate between mild and more severe phenotypes. As the advanced forms of these tests also measure the effects of platelets, it has been argued that they are more sensitive to differentiate phenotypes. We conclude that the origin of the large heterogeneity of phenotypes in severe hemophilia is multifactorial. As they produce no FVIII, patients with severe hemophilia and an intron 22 inversion are ideal candidates to study further bleeding variability. Until other parameters have been identified, the heterogeneity of the clinical phenotype may best be predicted by the first onset of the clinical features. At the moment, age at first joint bleed seems to be the most reliable factor to differentiate between phenotypes.

Related Concept Videos

Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pedigree Analysis01:35

Pedigree Analysis

Overview
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.